ChemoCentryx to Hold First Quarter 2021 Financial Results Conference Call on Thursday, April 29, 2021

Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) will release its first quarter 2021 financial results on April 29, 2021, post market close. A conference call to discuss these results will follow at 5:00 p.m. ET. ChemoCentryx is known for developing treatments for inflammatory diseases and cancer, with its lead candidate, avacopan (CCX168), under FDA review after a successful Phase III trial for ANCA-associated vasculitis. The drug is also in late-stage development for other serious conditions.

Positive

• Lead drug candidate avacopan (CCX168) completed a pivotal Phase III trial successfully.
• New Drug Application for avacopan is under review by the FDA.

Negative

• None.

MOUNTAIN VIEW, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2021 financial results will be released after market close on Thursday, April 29, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on April 29, 2021 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 3963565. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 Glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

FAQ

When will ChemoCentryx release its Q1 2021 financial results?

ChemoCentryx will release its Q1 2021 financial results on April 29, 2021.

What is the lead drug candidate of ChemoCentryx?

ChemoCentryx's lead drug candidate is avacopan (CCX168).

What is the status of avacopan's FDA review?

Avacopan is currently under review by the U.S. Food and Drug Administration.

What time is the ChemoCentryx conference call?

The ChemoCentryx conference call is scheduled for 5:00 p.m. ET on April 29, 2021.